Cargando…
PB2319: ZUMA-23: A GLOBAL, PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD OF CARE AS FIRST-LINE THERAPY IN PATIENTS WITH HIGH-RISK LARGE B-CELL LYMPHOMA
| Autores principales: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429721/ http://dx.doi.org/10.1097/01.HS9.0000975996.32786.92 |
| _version_ | 1785090782401658880 |
|---|---|
| author | Westin, Jason Jacobson, Caron Chavez, Julio C Sureda, Anna Morschhauser, Franck Glass, Bertram Dickinson, Michael Davies, Andrew J. Flinn, Ian W. Maloney, David Chamuleau, Martine Tees, Michael Xue, Allen Shahani, Shilpa Nikolajeva, Olga Kang, Janet Kaplan, Aida Schupp, Marco Miao, Harry Rich, Elizabeth Shima |
| author_facet | Westin, Jason Jacobson, Caron Chavez, Julio C Sureda, Anna Morschhauser, Franck Glass, Bertram Dickinson, Michael Davies, Andrew J. Flinn, Ian W. Maloney, David Chamuleau, Martine Tees, Michael Xue, Allen Shahani, Shilpa Nikolajeva, Olga Kang, Janet Kaplan, Aida Schupp, Marco Miao, Harry Rich, Elizabeth Shima |
| author_sort | Westin, Jason |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10429721 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104297212023-08-17 PB2319: ZUMA-23: A GLOBAL, PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD OF CARE AS FIRST-LINE THERAPY IN PATIENTS WITH HIGH-RISK LARGE B-CELL LYMPHOMA Westin, Jason Jacobson, Caron Chavez, Julio C Sureda, Anna Morschhauser, Franck Glass, Bertram Dickinson, Michael Davies, Andrew J. Flinn, Ian W. Maloney, David Chamuleau, Martine Tees, Michael Xue, Allen Shahani, Shilpa Nikolajeva, Olga Kang, Janet Kaplan, Aida Schupp, Marco Miao, Harry Rich, Elizabeth Shima Hemasphere Publication Only Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10429721/ http://dx.doi.org/10.1097/01.HS9.0000975996.32786.92 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Publication Only Westin, Jason Jacobson, Caron Chavez, Julio C Sureda, Anna Morschhauser, Franck Glass, Bertram Dickinson, Michael Davies, Andrew J. Flinn, Ian W. Maloney, David Chamuleau, Martine Tees, Michael Xue, Allen Shahani, Shilpa Nikolajeva, Olga Kang, Janet Kaplan, Aida Schupp, Marco Miao, Harry Rich, Elizabeth Shima PB2319: ZUMA-23: A GLOBAL, PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD OF CARE AS FIRST-LINE THERAPY IN PATIENTS WITH HIGH-RISK LARGE B-CELL LYMPHOMA |
| title | PB2319: ZUMA-23: A GLOBAL, PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD OF CARE AS FIRST-LINE THERAPY IN PATIENTS WITH HIGH-RISK LARGE B-CELL LYMPHOMA |
| title_full | PB2319: ZUMA-23: A GLOBAL, PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD OF CARE AS FIRST-LINE THERAPY IN PATIENTS WITH HIGH-RISK LARGE B-CELL LYMPHOMA |
| title_fullStr | PB2319: ZUMA-23: A GLOBAL, PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD OF CARE AS FIRST-LINE THERAPY IN PATIENTS WITH HIGH-RISK LARGE B-CELL LYMPHOMA |
| title_full_unstemmed | PB2319: ZUMA-23: A GLOBAL, PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD OF CARE AS FIRST-LINE THERAPY IN PATIENTS WITH HIGH-RISK LARGE B-CELL LYMPHOMA |
| title_short | PB2319: ZUMA-23: A GLOBAL, PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD OF CARE AS FIRST-LINE THERAPY IN PATIENTS WITH HIGH-RISK LARGE B-CELL LYMPHOMA |
| title_sort | pb2319: zuma-23: a global, phase 3, randomized controlled study of axicabtagene ciloleucel versus standard of care as first-line therapy in patients with high-risk large b-cell lymphoma |
| topic | Publication Only |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429721/ http://dx.doi.org/10.1097/01.HS9.0000975996.32786.92 |
| work_keys_str_mv | AT westinjason pb2319zuma23aglobalphase3randomizedcontrolledstudyofaxicabtageneciloleucelversusstandardofcareasfirstlinetherapyinpatientswithhighrisklargebcelllymphoma AT jacobsoncaron pb2319zuma23aglobalphase3randomizedcontrolledstudyofaxicabtageneciloleucelversusstandardofcareasfirstlinetherapyinpatientswithhighrisklargebcelllymphoma AT chavezjulioc pb2319zuma23aglobalphase3randomizedcontrolledstudyofaxicabtageneciloleucelversusstandardofcareasfirstlinetherapyinpatientswithhighrisklargebcelllymphoma AT suredaanna pb2319zuma23aglobalphase3randomizedcontrolledstudyofaxicabtageneciloleucelversusstandardofcareasfirstlinetherapyinpatientswithhighrisklargebcelllymphoma AT morschhauserfranck pb2319zuma23aglobalphase3randomizedcontrolledstudyofaxicabtageneciloleucelversusstandardofcareasfirstlinetherapyinpatientswithhighrisklargebcelllymphoma AT glassbertram pb2319zuma23aglobalphase3randomizedcontrolledstudyofaxicabtageneciloleucelversusstandardofcareasfirstlinetherapyinpatientswithhighrisklargebcelllymphoma AT dickinsonmichael pb2319zuma23aglobalphase3randomizedcontrolledstudyofaxicabtageneciloleucelversusstandardofcareasfirstlinetherapyinpatientswithhighrisklargebcelllymphoma AT daviesandrewj pb2319zuma23aglobalphase3randomizedcontrolledstudyofaxicabtageneciloleucelversusstandardofcareasfirstlinetherapyinpatientswithhighrisklargebcelllymphoma AT flinnianw pb2319zuma23aglobalphase3randomizedcontrolledstudyofaxicabtageneciloleucelversusstandardofcareasfirstlinetherapyinpatientswithhighrisklargebcelllymphoma AT maloneydavid pb2319zuma23aglobalphase3randomizedcontrolledstudyofaxicabtageneciloleucelversusstandardofcareasfirstlinetherapyinpatientswithhighrisklargebcelllymphoma AT chamuleaumartine pb2319zuma23aglobalphase3randomizedcontrolledstudyofaxicabtageneciloleucelversusstandardofcareasfirstlinetherapyinpatientswithhighrisklargebcelllymphoma AT teesmichael pb2319zuma23aglobalphase3randomizedcontrolledstudyofaxicabtageneciloleucelversusstandardofcareasfirstlinetherapyinpatientswithhighrisklargebcelllymphoma AT xueallen pb2319zuma23aglobalphase3randomizedcontrolledstudyofaxicabtageneciloleucelversusstandardofcareasfirstlinetherapyinpatientswithhighrisklargebcelllymphoma AT shahanishilpa pb2319zuma23aglobalphase3randomizedcontrolledstudyofaxicabtageneciloleucelversusstandardofcareasfirstlinetherapyinpatientswithhighrisklargebcelllymphoma AT nikolajevaolga pb2319zuma23aglobalphase3randomizedcontrolledstudyofaxicabtageneciloleucelversusstandardofcareasfirstlinetherapyinpatientswithhighrisklargebcelllymphoma AT kangjanet pb2319zuma23aglobalphase3randomizedcontrolledstudyofaxicabtageneciloleucelversusstandardofcareasfirstlinetherapyinpatientswithhighrisklargebcelllymphoma AT kaplanaida pb2319zuma23aglobalphase3randomizedcontrolledstudyofaxicabtageneciloleucelversusstandardofcareasfirstlinetherapyinpatientswithhighrisklargebcelllymphoma AT schuppmarco pb2319zuma23aglobalphase3randomizedcontrolledstudyofaxicabtageneciloleucelversusstandardofcareasfirstlinetherapyinpatientswithhighrisklargebcelllymphoma AT miaoharry pb2319zuma23aglobalphase3randomizedcontrolledstudyofaxicabtageneciloleucelversusstandardofcareasfirstlinetherapyinpatientswithhighrisklargebcelllymphoma AT richelizabethshima pb2319zuma23aglobalphase3randomizedcontrolledstudyofaxicabtageneciloleucelversusstandardofcareasfirstlinetherapyinpatientswithhighrisklargebcelllymphoma |